Peak Minerals Limited

PUA

Peak Minerals Ltd. engages in the exploration and evaluation of gold, copper, and nickel deposits in Australia. The firm offers a diversified multi-commodity portfolio of under-explored Australian copper and nickel assets. Its Western Australian Copper Projects consist of Green Rocks, Earaheedy Project, Kimberley South, and Carson. The Green Rocks Project is located approximately 35 kilometers (km) to the southeast of Meekatharra and covers 234 square kilometers (km2). The Earaheedy Project is located 28 km southeast of Degrussa Copper-gold Mine. The tenure consists of the Cork Tree and Merah Prospects. The company operates seven projects in the East Kimberley divided into magmatic sulfide or sedimentary copper related mineralization. The Magmatic sulphide projects are McGowan, Lamboo and Ten Minute. The sedimentary copper targets are Ilmars, Dead Horse, Kinahan and Carson. The company also owns 80% intertest in the highly prospective Kitongo and Lolo Uranium Projects, and the Minta Rutile Project in Cameroon, West Africa.

Prescient Therapeutics Limited

PTX

Prescient Therapeutics Ltd. is a biopharmaceutical company, which engages in the discovery and development of novel immunotherapeutic products for the treatment of chronic infectious diseases and cancer. The company is headquartered in South Melbourne, Victoria. The firm is developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 has completed Phase Ib expansion cohort study in relapsed and refractory T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. OmniCAR is a universal immune receptor platform being developed to enable controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumors. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumor microenvironment.